MDXH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 19:08):

Stats
Dzisiejszy wolumen	6 205.00
Średni wolumen	71 966.00
Kapitalizacja rynkowa	68.82M
EPS	$0 ( 2024-03-06 )
Następna data zysków	( $-0.300 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.200
ATR14	$0.0160 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-03	Mvm Partners, Llc	Buy	1 000 000	Common Stock
2021-11-04	Mvm Partners Llp	Buy	0	Common Stock

INSIDER POWER
100.00
Last 1 transactions
Buy: 1 000 000 \| Sell: 0

Wolumen Korelacja

Długi: 0.21 (neutral)

Krótki: -0.14 (neutral)

Signal:(58.5) Neutral

MDxHealth SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MDxHealth SA Korelacja - Waluta/Towar

-0.23
( neutral )

-0.51
( weak negative )

0.00
( neutral )

0.17
( neutral )

-0.12
( neutral )

MDxHealth SA Finanse

Annual	2023
Przychody:	$70.19M
Zysk brutto:	$39.44M (56.18 %)
EPS:	$-1.660

FY	2023
Przychody:	$70.19M
Zysk brutto:	$39.44M (56.18 %)
EPS:	$-1.660

FY	2022
Przychody:	$37.05M
Zysk brutto:	$19.22M (51.87 %)
EPS:	$-3.16

FY	2021
Przychody:	$22.24M
Zysk brutto:	$10.41M (46.82 %)
EPS:	$-2.40

Financial Reports:

No articles found.

MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.